Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 belzutifan monotherapy study in advanced PPGL, pNET, VHL-associated tumors, wt GIST, and solid tumors with HIF-2alpha-related genetic alterations
2020-005028-13Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), islet cell tumor and 3 more, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Mar 2021; status: active.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)islet cell tumorvon Hippel–Lindau disease (VHL)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2020-005028-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005028-13.